The addition of CDK4/6 inhibitors to endocrine therapy, either in the first-line setting or after progression to an aromatase inhibitor, significantly improved progression-free and overall survival compared to endocrine therapy alone in the treatment of post- and premenopausal women with advanced HR-positive HER2-negative breast cancer. The gene discussed is CYP19A1; the disease is breast carcinoma.